Whyte J, Soriano E, Earnshaw W C, McHugh N J
Bath Institute for Rheumatic Diseases, Johns Hopkins University, Baltimore, Maryland, USA.
Br J Rheumatol. 1995 May;34(5):407-12. doi: 10.1093/rheumatology/34.5.407.
The carboxyl-terminal fragment of CENP-B contains a major epitope for anti-centromere antibodies (ACA). We have developed an enzyme-linked immunoassay (ELISA) for measuring antibodies to the 147-carboxyl-terminal amino acids of CENP-B expressed as a beta-galactosidase fusion protein. The ELISA was 98% sensitive and 95% specific for detecting ACA in a population which included 46 patients with ACA detected by other means. Therefore, the CENP-B ELISA should prove a valuable tool in screening for ACA in populations at risk of developing systemic sclerosis, such as those with Raynaud's phenomenon. Levels of anti-CENP-B antibodies were not increased in unaffected relatives of probands with ACA.
CENP - B的羧基末端片段包含抗着丝粒抗体（ACA）的主要表位。我们开发了一种酶联免疫吸附测定（ELISA）法，用于检测针对以β - 半乳糖苷酶融合蛋白形式表达的CENP - B的147个羧基末端氨基酸的抗体。在一个包含46例通过其他方法检测出ACA的患者群体中，该ELISA检测ACA的灵敏度为98%，特异性为95%。因此，CENP - B ELISA在筛查有患系统性硬化症风险的人群（如患有雷诺现象的人群）中的ACA时应是一种有价值的工具。ACA先证者的未患病亲属中抗CENP - B抗体水平未升高。
